Predictheon closes a €1.8 million funding round with the participation of Grow Venture Partners, Zubi Capital, Namarel and Capital Cell

Predictheon has secured a €1.8 million funding round to advance the commercialization phase of its product. The majority of the investment comes from Grow Venture Partners, which will deploy capital from the Catalan public fund FITA and the European Investment Fund (EIF). The round also included participation from Zubi Capital, Namarel Ventures — an investment firm linked to one of the Rubiralta brothers, the family behind Werfen—and independent investors through Capital Cell.

Predictheon is revolutionizing patient safety and healthcare efficiency through an AI-driven platform that enables anesthesiologists to centralize critical data into a single intelligent interface capable of predicting imminent complications during surgical procedures.

By supporting this innovative technology, investors reaffirm their commitment to purpose-driven startups that improve lives and address structural challenges in healthcare systems. The funds raised will be instrumental in advancing commercialization, securing regulatory approvals, and conducting upcoming clinical trials.

Following the funding, the company will focus on obtaining regulatory approval for its solution—a process that may take up to two years—and on initiating clinical trials. In parallel, it will continue to seek opportunities to conduct additional pilot testing.

Predictheon estimates a timeline of approximately two years to reach the market, targeting a potential launch by 2028. The company is already in discussions with senior executives from major multinational medical device companies that have shown interest in its technology. In this context, Predictheon is considering several strategic paths, including partnerships to integrate its software into third-party devices, distribution agreements, or a potential acquisition. The company does not intend to lead large-scale commercialization efforts itself, recognizing the structural limitations of a company of its size in addressing global markets independently